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ABSTRACT
Introduction: Atherosclerosis is an inflammatory disease causing a vast array of cardiovascular diseases.
Adipophilin has been reported to be highly expressed in atherosclerotic lesions. This study investigated
the possible existence of auto-reactive T cells against an HLA-A02-restricted adipophilin-derived
peptide as well as peptides from Epstein-barr virus (EBV), Cytomegalovirus (CMV) and influenza
(Flu) virus in patients with atherosclerosis. Methods: HLA-A02 expression on peripheral blood
mononuclear cells (PBMCs) was examined by flow cytometry. PBMCs from HLA-A02 individuals were
stimulated with adipophilin, CMV, EBV, and Flu peptides at a concentration of 10 mM. Interferon
(IFN)-g production was evaluated in the culture supernatant using a commercial ELISA test. Results:
The levels of IFN-g production against an HLA-A02-restricted adipophilin peptide and peptides from
CMV, EBV, and Flu revealed no statistically significant differences between patients and healthy
controls. However, we found a positive correlation between IFN-g production against adipophilin and
Body mass index (BMI) of patients (R 5 0.8, P 5 0.003), whereas no significant correlation was found
in healthy controls (R 5 0.267, P 5 0.378). No correlation between BMI and IFN-g production
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against CMV, EBV, or Flu peptides was found. Discussion: Atherosclerotic patients with higher BMIs
might have greater numbers of T cells against adipophilin that is highly expressed in atherosclerotic
plaques. Therefore, autoimmune reactions may have a greater role in the development of athero-
sclerosis in individuals with higher BMI.
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INTRODUCTION
Atherosclerosis is a chronic immune inflammatory disease of the arterial walls characterized by
formation of atherosclerotic plaques [1]. The major clinical manifestations of the disease are
peripheral arterial disease, ischemic heart pain, myocardial infarction and ischemic stroke which
lead to premature death worldwide [2]. While the exact etiology of atherosclerosis is unknown, it
is widely accepted that it is a multifactorial disease; for example with contribution of infections
and the immune system [2–4].
The contribution of immune cells in the disease process is well acknowledged, and a large
body of evidence suggests the underlying importance of the immune system in the devel-
opment and progression of atherosclerosis [1, 5]. Various infiltrating immune cell types,
including monocytes/foam cell macrophages and lymphocytes with their secreted cytokines
and chemokines constitute key components of atherosclerotic plaque inflammation [1].
Monocytes can be recruited to the inflamed endothelium where they differentiate into
macrophage phenotypes with highly phagocytic ability. They can scavenge modified low-
density lipoprotein (mLDL) and eventually form foam cells, which along with other immune
cells can increase the risk of the development of the unstable atherosclerotic plaque
phenotype [5].
In addition, other immune cells including CD4þ T helper and CD8þ cytotoxic T lym-
phocytes (CTLs) play a pivotal role in the development or instability of the plaque [6, 7]. It is
suggested that CD8þ T cells represent about 29% of all lymphocytes in early lesions, increasing
up to 50% in advanced plaques [6]. They play critical roles in the development of vulnerable
atherosclerotic plaques by recognition of oxidized low-density lipoprotein (Ox-LDL)-derived
peptides and other probable auto-antigens presented via MHC class I molecules [8]. The
cytotoxic effects of CD8þ T cells happen via granule exocytosis and release of key effector
molecules, perforin and granzymes by which they induce apoptosis in different target cells
including smooth muscle cells, endothelial cells and macrophages, and eventually lead to
necrotic core and vulnerable atherosclerotic plaques formation [7]. Moreover, several cytokines
produced by CD8þ T cells, like tumor-necrosis factor (TNF)-a and interferon (IFN)-g can exert
cytotoxic action when secreted in the proximity of target cells [9]. The central role of IFN-g in
pathogenesis of atherosclerosis is shown in IFN-g-deficient mice which develop smaller and
more stable plaques [10].
This cytokine is highly expressed in atherosclerotic lesions and exerts its detrimental
roles in atherosclerosis via different mechanisms; IFN-g activates macrophage and
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endothelial cells to produce chemokines and adhesion molecules, respectively, by which it
provokes monocyte/lymphocyte recruitment and infiltration into the sub-endothelium, thus
accelerating plaque growth. IFN-g promotes foam cell formation by increasing the uptake of
mLDL by scavenger receptors on macrophages. IFN-g can also help formation of vulnerable
plaques by inducing the formation and release of reactive oxygen species and matrix met-
alloproteinases (MMPs) [11].
Numerous atherosclerosis-related T cell antigens are reported which include both microbial
and self-antigens. Among bacterial and viral pathogens, Chlamydia pneumoniae, Helicobacter
pylori, Porphyromonas gingivalis, Cytomegalovirus (CMV), Epstein-barr virus (EBV) and
influenza (Flu) virus [12] are documented. The proposed mechanisms in microbial pathogenesis
in atherosclerosis include direct infection of cells in the arterial wall, molecular mimicry, acti-
vation of pattern recognition receptors (PRR; e.g. Toll-like receptor; TLR) and subsequent
bystander activation of auto-reactive T-cells and epitope spreading. Another mechanism is
based on “danger hypothesis” in which damage-associated molecular patterns (DAMPs)
released during cell death act as endogenous self-adjuvants and induce inflammation and auto-
reactive T cell responses [13].
Potential candidate T cell auto-antigens in atherosclerosis lie within altered self-structures,
such as modified lipoproteins and other proteins including b2-glycoprotein I and heat shock
proteins [14].
Adipophilin, or adipose differentiation-related protein (ADRP) is a 50 kDa protein expressed
in adipocytes, which controls the structure and formation of lipid droplets. It is also expressed in
macrophage foam cells and its expression is up-regulated by mLDL [15, 16]. This protein is
expressed at higher levels in atherosclerotic lesions compared to healthy arterial intima, and the
relative expression of adipophilin is higher in symptomatic compared to asymptomatic carotid
plaques [15]. In addition, studies have shown that adipophilin is highly overexpressed in some
tumors and is a target of CD8þ T cell responses [17]. In a study conducted by Weinschenk et al.
a HLA-A*0201-binding peptide, SVASTITGV, derived from the adipophilin protein was
identified in renal cell carcinoma (RCC) tumor samples [18] which was further confirmed by
other studies [17]. As adipophilin is highly expressed in atherosclerotic lesions, and previous
experimental data have revealed the “SVASTITGV” peptide as a CD8þ T cell target, we
examined the possible potential of this peptide as a CD8þ T-cell epitope that can induce an-
tigen-specific CD8þ T cells in HLA-A2 atherosclerosis patients.
The existence of CD8þ T-cells specific to adipophilin-derived peptides in patients with
cancers has already been shown [17]. Therefore, we hypothesized that adipophilin could be a
potential target for T cells in atherosclerosis [16, 19]. Thus the purpose of the present study was
to investigate the possible existence of auto-reactive T cells against an HLA-A02-restricted




Thirty-two patients with atherosclerosis from the Diabetes Clinic of Shiraz University of
Medical Sciences, Iran entered the study. Forty age- and sex-matched healthy blood donors
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were also enrolled in the study. Informed consent was obtained from all the subjects and the
study was approved by the relevant Ethics Committees. Coronary angiography (CAG) was
performed by a team of expert interventional cardiologists to estimate the coronary lesions.
The inclusion and exclusion criteria were as follows: patients who were diagnosed based on
the results of coronary angiography were included in the present study. We excluded pa-
tients with chronic diseases, including diabetes, hepatic or renal diseases or active infection.
Patients with autoimmune diseases, malignancies and histories of taking any immunosup-
pressive drugs during last 3 months were also excluded from this study. For healthy subjects,
the exclusion criteria were current smoking, hypertension, hypercholesterolemia, diabetes,
obesity, active infection, autoimmune disease. The patients were grouped into single vessel
disease (SVD), double vessel disease (DVD), and triple vessel disease (TVD) according to the
number of major epicardial coronary arteries involved. Blood samples from both patients
and controls were collected in heparin tubes and kept at room temperature (RT) until
processing.
Peptides
HLA-A2-restricted peptides used in this study were >80% pure (China Peptides, Shanghai,
China) (Table 1). Peptides were added at a final concentration of 10 mM.
Isolation of peripheral blood mononuclear cells (PBMCs)
Ficoll-Hypaque solution (Lymphodex, Germany) was placed into a 50-mL conical centrifuge
tube using a sterile pipette. Heparinized blood was mixed with an equal volume of phosphate
buffered saline (PBS) and the diluted blood was slowly layered over the Ficoll-Hypaque solution.
The tube was centrifuged for 20 min at 4003g, 22 8C. The ring of mononuclear cells was
carefully collected and transferred into a 15-mL conical tube, 10 mL complete Roswell Park
Memorial Institute (RPMI) medium was added and mixed thoroughly. The tube was centrifuged
for 10 min at 4003g, 4 8C. The supernatant was discarded and peripheral blood mononuclear
cells (PBMCs) were used for further experiments.
HLA-A02 typing of PBMCs by flow cytometry
106 PBMCs were re-suspended in 1 mL ice-cold PBS containing 10% fetal calf serum (FCS) and
1% sodium azide to prevent the modulation and internalization of surface antigens which can
Table 1. HLA-A02-restricted peptides used in the stimulation of cultured PBMCs
HLA-A2-restricted peptides Sequences SYFPEITHI score References
adipophilin129-137 SVASTITGV 25 [17]
Flu MP58-66 GILGFVFTL 30 [20]
EBV280-288 GLCTLVAML 28 [20]
CMV495-503 NLVPMVATV 30 [20]
Flu MP, Influenza Matrix protein; EBV, Epstein-Barr virus; CMV, Cytomegalovirus; SYFPEITHI
(a database for MHC ligands and peptide motifs).
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decrease the fluorescence intensity. 100 mL of cell suspension was added to each eppendorf tube,
2 mg of anti HLA-A02 monoclonal antibody (mouse IgG2b, Abcam, USA) was added to the cell
suspension (final concentration 20 mg/mL), and cells were incubated for at least 30 min at 4 8C
in the dark. Anti HLA-Class I antibody (IgG2a, Abcam, USA) was used as positive control. Cells
were washed three times by centrifugation for 5 min at 4003g and re-suspended in ice-cold PBS.
10 mL of fluorescent isothiocyanate (FITC)-conjugated anti-mouse IgG secondary antibody
(IgG2a, Abcam, USA) was added and incubation was continued for 30 min at 4˚C in the dark.
Cells stained only with the secondary antibody were used as negative control. In the next step,
cells were washed 3 times by centrifugation for 5 min at 4003g and re-suspended in ice-cold
PBS containing 3% bovine serum albumin (BSA) and 1% sodium azide. The cell suspension was
analyzed in a BD FACSCalibur flow cytometer. Analysis was performed by FlowJo version 7
software (TreeStar, USA).
PBMCs culture and stimulation with specific peptides
PBMCs from HLA-A02 individuals (n 5 14) were seeded in 96-well plates (Nunc, Denmark)
at a concentration of 2 3 105 cells/well. PBMCs cultured alone were used as negative
control. Phytohemagglutinin (PHA) (Invitrogen, USA) at a final concentration of 2.5 mg/mL
was used as positive control of the kit. Flu, CMV, and EBV peptides at a concentration of 10
mM/well/200 mL were used as positive controls for the subjects [20]. Adipophilin peptide was
also used at the mentioned concentration to determine the responsiveness of PBMCs [17].
Plates were incubated at 5% CO2 in a humidified incubator for 24 h. Cell culture media were
next collected and centrifuged (1,500 rpm, 4 8C for 10 min). Supernatants were kept at 80
8C until use for further processing. The sequences of selected peptides used in the present
study were listed in Table 1.
IFN-g detection in the supernatant of cultured PBMCs using ELISA
IFN-g in the culture supernatant was assessed by using a commercial ELISA kit (Human
IFN gamma ELISA Ready-SET-Go, ebioscience, USA) (sensitivity: 4 pg/mL) based on the
manufacturer’s instructions. Briefly, the ELISA plate was coated with 100 mL/well of
capture antibody in coating buffer. The plate was sealed and incubated overnight at 4 8C.
Wells were aspirated and washed 5 times with >250 mL/well wash buffer (1 3 PBS, 0.05%
Tween-20) and allowed to soak for about 1 minute during each wash step to increase the
effectiveness of the washes. The plate was blotted on absorbent paper to remove any re-
sidual buffer. 1 part of 5X concentrated assay diluent was diluted with 4 parts Deionized
(DI) water and blocking was done using 200 mL/well of fetal bovine serum (FBS) 2%. The
plate was incubated at room temperature for 1 hour. Wells were aspirated/washed as in
step 3 (5 washes). Standards were diluted using 1X assay diluent. 100 mL/well of standard
was added to the appropriate wells. Two-fold serial dilutions of the top standards were
made to make the standard curve. 100 mL/well of the cell culture supernatant was added to
the appropriate wells, and the plate was covered or sealed and incubated overnight at 4 8C
for maximal sensitivity. The next day, wells were aspirated/washed as in step 3 (5 washes).
100 mL/well of detection antibody diluted in 1X assay diluent was added, and the plate was
sealed and incubated at room temperature for 1 hour. Wells were aspirated/washed as in
step 3 (5 washes). 100 mL/well of Avidin-HRP diluted in 1X assay diluent was added, and
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the plate was sealed and incubated at room temperature for 30 minutes. Wells were
aspirated, washed, and soaked (7 washes). 100 mL/well of substrate solution was added to
each well, and the plate was incubated at room temperature for 15 min. 50 mL of stop
solution (2N H2SO4) was added to each well. The plate was read at 450 nm and a 630 nm
filter as a reference wavelength. The levels of IFN-g within the sample were determined by
setting up a standard curve of known target protein concentrations which was provided in
the kit.
Statistical analysis
Data presented in the text and Figures are mean ± SEM of at least three independent experi-
ments. Unpaired Mann-Whitney U test and Kruskal-Wallis test were used to test the probability
of significant differences between groups. For testing the correlation between the levels of IFN-g
and clinical manifestation, Pearson’s correlation test was used. A Pvalue less than 0.05 was
considered statistically significant.
RESULTS
HLA typing of patients and healthy individuals
HLA typing using flow cytometry revealed that 14 out of the 32 recruited patients with
atherosclerosis and 16 out of the 40 healthy individuals were positive for HLA-A02
(Fig. 1). Angiography indicated that five out of the 14 HLA-A02 patients had SVD, three
had DVD and six had three-vessel disease (3VD). All HLA-A02 individuals were used for
Fig. 1. HLA typing using flow cytometry. Dot plot and histogram plot obtained from flow cytometry
analysis of PBMCs isolated from patients and healthy individuals. (A) Unstained; (B) Negative control; (C)
Positive control; (D) HLA-A02-positive individual.
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further experiments. The demographic characteristics of the two groups are listed in
Table 2.
ELISA on PBMCs supernatant
The levels of IFN-g (pg/mL) for HLA-A2-positive patients and controls after stimulation
with CMV, EBV, Flu- and adipophilin-derived peptides are shown in Table 3. PBMCs
stimulation with the mentioned peptides revealed no statistically significant differences in
the levels of IFN-g production between HLA-A2-positive patients and healthy controls
(Fig. 2).
Correlation between IFN-g and clinicopathologic manifestations of atherosclerosis in
patients group
The results of the correlation analysis are shown in Table 4. Interestingly, a positive cor-
relation was found between levels of IFN-g production against adipophilin and Body Mass
Index (BMI) of patients (R 5 0.8, P 5 0.003). No significant differences were found between
the levels of IFN-g against adipophilin and other clinicopathologic manifestations. In
respect to the other selected peptides, no significant correlations were found between IFN-g
production and clinical manifestations. In addition, the same analysis was done in healthy
controls to predict the correlation between IFN-g productions against adipophilin and BMI.
No statistically significant correlation was seen (R 5 0.267, P 5 0.378). The same results
Table 2. Demographic characteristics of atherosclerosis patients and healthy controls




HLA-A2þ 14 (43%) 16 (40%)
Age (year) 41.2 ± 1.03 36.6 ± 0.9
BMI (body mass index) 24.8 ± 0.7 22.95 ± 2.20
Sex: F/M 10/4 10/6
Data represent mean ± SEM of age and BMI.
Table 3. The levels of IFN-g (pg/mL) for HLA-A2-positive patients and healthy controls after PBMCs
stimulation with CMV-, EBV-, Flu- and adipophilin-derived peptides
Peptides Patients (n 5 14) Controls (n 5 16)
P
value
CMV495-503 83.3 ± 27.6 70.6 ± 14.8 0.68
EBV280-288 39.0 ± 3.3 46.1 ± 9.7 0.5
Flu MP58-66 47.8 ± 8.9 49.2 ± 9.5 0.92
adipophilin 129-137 36.9 ± 2.4 42.7 ± 8.8 0.53
Flu MP, Influenza (matrix protein); EBV, Epstein-Barr virus; CMV, Cytomegalovirus.
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were obtained when we pooled the results of IFN-g of healthy subjects and atherosclerosis
patients together. In this case no correlation was seen between IFN-g and BMI (R 5 0.140,
P 5 0.514).
Fig. 2. IFN-g ELISA results in PBMCs cultured with CMV-, EBV-, Flu- and Adipo-derived peptides.
As shown, the levels of IFN-g between HLA-A2-positive patients and healthy blood donors exhibit no
significant differences
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0.454 0.191 0.109 0.814 0.151 0.903 0.610 0.520
0.089 0.532 0.750
IFN-EBV 0.414 0.116 0.482 0.195 0.296 0.391 0.174 0.354
0.125 0.705 0.133
IFN-Flu 0.259 0.443 0.257 0.806 1.000 0.606 1.000 0.946
0.500 0.272 0.623
BMI, Body mass index; BP, Blood pressure; IFN, Interferon-gamma; Adipo, adipophilin; CMV, Cytomegalovirus; EBV, Epstein-Barr virus; Flu, Influenza








In the current study we found that HLA-A2-restricted adipophilin129-137 is recognized by T cells
from patients with atherosclerosis as well as control individuals. The magnitude of IFN-g
response was comparable to that of EBV280-288 and Flu MP58-66 (Fig. 2). Both patients and
controls produced notable amounts of IFN-g in response to CMV495-503.
Adipophilin is expressed in a broad variety of human malignancies and the HLA-A*02-
binding peptide derived from this protein was identified in tumors of RCC patients [17]. A
previous study reported that CTLs can lyse different cancer cells which endogenously express
the adipophilin-derived peptides in a HLA-A*0201-restricted manner [16]. CTLs in RCC,
malignant melanoma, breast cancer, and multiple myeloma cells can recognize and lyse tumor
cells which endogenously express adipophilin in an antigen-specific and HLA-A2-restricted
manner [17]. Adipophilin is also shown to be highly expressed in the atherosclerotic plaque [15].
Since the T cells in the circulation home to different tissues as well as pathologic sites, we asked
if T (CD8þ) cell responses towards adipophilin129-137 exist in our patients and if so, how
different these responses would be from that of healthy controls. While such responses in the
form of IFN-g secretion existed in both groups, we did not find any significant difference be-
tween the two groups. However, we found a positive correlation between the extent of IFN-g
production upon adipophilin peptide stimulation and BMI only among patients. Interestingly,
such a correlation did not exist in healthy controls or when both groups were considered. Our
result supports the relationship between inflammation induced by obesity and atherosclerosis.
Studies have shown that obesity is associated with the production of inflammatory molecules,
including inflammatory cytokines. The inflammatory cytokines, by affecting the artery wall, lead
to the production of different mediators and surface proteins, followed by accumulation of
inflammatory cells, endothelial dysfunction, substantial structural change in the artery and ul-
timately to atherosclerosis [21]. Earlier studies have demonstrated that the risk of cardiovascular
disease (CVD) significantly increases in obese individuals in comparison to those with normal
BMI [22, 23]. As noted above, high adipophilin expression in atherosclerotic plaques has already
been reported [15]. Furthermore, association of total plaque area with obesity is demonstrated in
a recent study [24]. Hence, we assume that atherosclerotic patients with higher BMI might have
a greater number of T cells against this protein. Adipophilin plays a very important role in the
formation of fat droplets, and the expression of this protein is very high in the adipose tissue of
obese people [25]. Accordingly, we suggest that our study provides new information on the
auto-reactive responses in general and in atherosclerosis in particular [17]. In our study both
patients and controls responded to peptides derived from CMV, EBV and Flu viruses. As already
mentioned, several evidences have indicated the relationship between pathogens and athero-
sclerosis [4, 12, 26]. The proposed mechanisms include direct presence of pathogens in the
plaques, molecular mimicry, activation of PRRs, bystander activation of auto-reactive T-cells
and epitope spreading [13].
We found no statistically significant differences in the levels of IFN-g against the CMV
peptide between HLA-A2-positive patients and healthy controls. Several studies indicate that
CMV infection may contribute to accelerated atherosclerosis [4, 27–31]. CMV infection has
been associated with accelerated heart transplant vasculopathy, cardiac allograft rejection and
atherosclerosis [32, 33]. A recent report has shown an association between CVD mortality and
CMV antibody titers [34]. Although there have been a large number of reports of the presence of
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CMV in human plaques [35–39], a number of studies failed to document the presence of CMV
in human lesions [40, 41]. The complex role of CMV in atherogenesis and the complex nature of
the disease make it difficult to draw any conclusion at this point.
In addition to the CMV, EBV is another herpesvirus that is related to the pathogenesis of
atherosclerosis [30]. A previous study indicated that EBV-specific cytotoxic T-cells and EBV
DNA could be frequently observed in human atherosclerotic plaques, therefore T-cell response
against EBV could contribute to plaque inflammation [42]. Our findings, however, did not show
any differences with respect to CD8þ T-Cell IFN-g responses against a common HLA-A2-
restricted EBV peptide between patients and controls. Also, there have been both positive and
negative reports of an association between Flu infection or seropositivity for Flu antibodies and
coronary artery disease [43–45]. However, IFN-g responses to FluMP58-66, while present, did not
differ between our studied groups. Obviously by using only one peptide we cannot rule out the
differences between patients and controls; however, the production of comparable amounts of
IFN-g induced by adipophilin, EBV and FLU peptides in our study is noteworthy.
This study set out for the first time to explore the presence of specific CD8þ T-cells against
adipophilin as an autoantigen in patients with atherosclerosis compared to healthy individuals.
Our results showed a high number of cells producing IFN-g against adipophilin in patients with
higher BMI. However, the results of this investigation show no significant differences between
the two groups; i.e. adipophilin129-137 is recognized by CD8þ T-cells from similar numbers of
patients and healthy blood donors as are EBV and Flu peptides. Therefore, auto-reactive re-
sponses may be more common than previously thought. It is possible that studying other
adipophilin-derived peptides would clarify the role of this molecule and specifically that of
CD8þ T-cells in atherosclerosis and other diseases. In addition, culturing and stimulating
plaque-derived CD8þ T-cells instead of PBMCs is a more accurate option for finding the
candidate antigenic peptides in atherosclerosis. Finally, using more sensitive techniques such as
ELISPOT and flow cytometry to investigate the production and secretion of IFN-g, or using
peptide tetramers could help us to find out the role of self and foreign antigens in the patho-
genesis of atherosclerosis.
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